VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,980 shares of the biopharmaceutical company’s stock, valued at approximately $1,198,000.

Several other hedge funds have also modified their holdings of ALNY. California State Teachers Retirement System lifted its position in Alnylam Pharmaceuticals by 30,461.4% during the 2nd quarter. California State Teachers Retirement System now owns 60,164,157 shares of the biopharmaceutical company’s stock worth $18,111,216,000 after acquiring an additional 59,967,294 shares in the last quarter. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $895,816,000. Legal & General Group Plc purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at $278,321,000. Qube Research & Technologies Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $369,943,000. Finally, AQR Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after purchasing an additional 555,759 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 0.5%

NASDAQ:ALNY opened at $248.68 on Friday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The business’s 50 day moving average is $254.43 and its two-hundred day moving average is $288.99. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The company has a market cap of $33.28 billion, a PE ratio of 46.22 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business’s quarterly revenue was up 66.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.51) EPS. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current year.

Wall Street Analyst Weigh In

ALNY has been the topic of several analyst reports. Stifel Nicolaus dropped their price target on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Jefferies Financial Group upped their price objective on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a research report on Tuesday, September 8th. Oppenheimer lowered their target price on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. BMO Capital Markets reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Finally, Chardan Capital reiterated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $376.67.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).